An interventional study of 40 IU Intranasal Oxytocin and Placebo in Borderline Personality Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Suspended at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Other
The study will examine behavioral patterns and underlying neural correlates which distinguish patients with borderline personality disorder (BPD) from healthy subjects as they participate in a two-person trust game and will determine whether administration of intranasal oxytocin (OT) will normalize trust game performance and concomitant neural processing in the BPD group.
This is a pilot study to support submission of a larger-scale federally funded study. The study is designed to develop new strategies for treating the severe interpersonal dysfunction in borderline personality disorder (BPD) by modeling the interpersonal disturbance in BPD in the laboratory, identifying its neural correlates and determining whether the social neuropeptide, oxytocin, can ameliorate the interpersonal dysfunction. The study will examine behavioral patterns and underlying neural correlates which distinguish patients with borderline personality disorder (BPD) from healthy subjects as they participate in a two-person trust game and will determine whether administration of intranasal oxytocin (OT) will normalize trust game performance and concomitant neural processing in the BPD group.
The specific aims of the study are: 1) to determine whether BPD patients and healthy controls (HC) differ in their pattern of investing in a trustee when the trustee behaves benevolently or malevolently towards them or suddenly becomes malevolent after a period of benevolence (or vice-versa) in a multi-round economic exchange game ("The Trust Game"), and 2) to determine the effect upon behavior of the administration of 40 IU intranasal oxytocin relative to placebo in BPD subjects and HC's engaged in the Trust Game.
Subjects are being recruited and may participate in the Trust Game task, but intranasal administration of oxytocin has temporarily been held because of the COVID-19 pandemic.
269 studies on the registry are indexed under Borderline Personality Disorder; 67 are open to participants now.
This study's planned enrollment of 40 is below the median of 70 across 215 interventional studies indexed under Borderline Personality Disorder.
Browse Borderline Personality Disorder studies →Icahn School of Medicine at Mount Sinai is the lead sponsor of 764 studies on the registry; 181 are open to participants now.
Of its 121 completed or terminated interventional studies of FDA-regulated products, 82 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
Drug: 40 IU Intranasal Oxytocin · Drug: Placebo · Drug: 24 IU intranasal Oxytocin
Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
Drug: 40 IU Intranasal Oxytocin · Drug: Placebo · Drug: 24 IU intranasal Oxytocin
40 IU intranasal oxytocin
Also known as: OT, Syntocin
Intranasal Placebo
Also known as: Intranasal Placebo
Also known as: syntocin, OT
Trust Game Affect Ratings
Behavioral differences between groups based on Scale with 1= most negative to 5=most positive
Time frame: up to 4 weeks
This study is suspended, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Borderline Personality Disorder→
Icahn School of Medicine at Mount Sinai